You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
CEO Miles White said that he still believes that Alere is a good strategic fit for Abbott, and the firm is pursuing all of the necessary regulatory approvals for the deal.
The company also reported FY2016 revenues rose 5 percent year over year, despite a dip in product revenues for the year.
The firm's confirmation that it is on track with current and Q3 financial report timing may not be enough to appease would-be acquirer Abbott.
An expansion of its oncology test menu helped drive installations of its Idylla molecular diagnostics system and cartridge sales in the first half of 2016.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
While Abbott continues to express concerns about the pending acquisition, Alere has remained resolute in its response.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The firm also reported that it has corrected immaterial errors in previous financial statements.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.